The Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone
Status:
Unknown status
Trial end date:
2018-03-03
Target enrollment:
Participant gender:
Summary
Aim: Comparing the efficacy and safety of intra-articular injection of tocilizumab and
compound betamethasone.
Study design: A randomized, single-blind, parallel controlled and one center trial design.
Sample size: 60 cases. Study content: Patients who meet inclusive criteria will be randomly
divided into tocilizumab group and compound betamethasone group. In the baseline period, the
investigators will collect patients' general information, disease information, disease
activity score, laboratory results and images of articular ultrasound. After 4 weeks of
injection, patients will be asked to come back, and their disease information, disease
activity score, laboratory results as well as images of articular ultrasound will be
collected. Finally, these data will be sorted and analyzed.
Hypothesis: The efficacy and safety of intra-articular injection of tocilizumab is better
than that of compound betamethasone.